Autoimmune encephalitis

What changes during this transition

This trigger exists in the Juno library to give the AI substrate honest answers when users (or, more commonly, the terrified family members of someone newly diagnosed) ask whether peptides have a role in autoimmune encephalitis. The answer, across the catalog, is no. We've drafted substrate for five peptides that come up in community searches around 'brain healing' or 'neuroprotection' or 'autoimmune' framings — BPC-157, Semax, Cerebrolysin, LL-37, and NMN — and every one of them is mechanistically misaligned with antibody-mediated CNS inflammation, or sits outside the indication register of the multi-jurisdictional evidence that supports it elsewhere, or actively pushes in the wrong therapeutic direction. Autoimmune encephalitis is a neurological emergency. The acute phase often requires ICU-level care — patients with anti-NMDAR encephalitis classically progress through a psychiatric prodrome, then seizures, then orofacial dyskinesias and other movement disorders, then autonomic instability, then coma; LGI1 patients present with faciobrachial dystonic seizures that are pathognomonic but often missed early; paraneoplastic patients can deteriorate rapidly if the underlying tumor isn't found. Rapid diagnosis and rapid initiation of first-line immunotherapy improve outcomes meaningfully. This isn't a context where the right move is to research peptide adjuncts; it's a context where the right move is to make sure the patient is being seen by a neurology service experienced in autoimmune CNS disease. The cancer screening point is genuinely load-bearing. For adult women with anti-NMDAR encephalitis, ovarian teratoma is present in roughly half of cases and teratoma removal dramatically improves outcomes — this is not screening that can be deferred. For GABA-B receptor encephalitis, the association with small-cell lung cancer means CT chest is essential and PET is often warranted if initial imaging is negative. For CASPR2 and AMPAR encephalitis, thymoma screening with chest CT and dedicated mediastinal imaging matters. For the classic paraneoplastic syndromes (anti-Hu, anti-Ma2, anti-CV2/CRMP5, anti-amphiphysin), the antibody itself points toward specific malignancies and the prognosis is fundamentally tied to whether the cancer is found and treated. Pediatric autoimmune encephalitis is a meaningful subpopulation. Anti-NMDAR encephalitis is one of the more common autoimmune encephalitides in children and there's overlap with ADEM presentations. Pediatric autoimmune neurology has its own treatment considerations — adjusting immunosuppression dosing, longer-term concerns about cumulative steroid exposure, developmental neuropsychology after recovery, school reintegration. Bringing consumer-grade peptides into a pediatric patient's regimen during active treatment with rituximab + IVIG + high-dose corticosteroids is not something any guideline or pediatric autoimmune neurology service supports. The recovery phase is long. Cognitive and psychiatric residua are common and often take months to years to resolve fully — sometimes they don't fully resolve. The work of recovery is done by autoimmune neurology (antibody titer surveillance, maintenance immunosuppression, relapse vigilance), neuropsychology (formal cognitive assessment, rehabilitation), psychiatry (residual mood symptoms, residual psychotic features especially after NMDAR encephalitis), physical and occupational therapy, and patient advocacy organizations (Autoimmune Encephalitis Alliance, Anti-NMDA Receptor Encephalitis Foundation, IAES — the International Autoimmune Encephalitis Society — all provide meaningful support resources). This recovery trajectory makes attribution of any peptide effect functionally impossible — natural recovery extends over a long enough timeframe that any apparent improvement attributed to an adjunct is indistinguishable from the expected course. Emerging therapeutics in this space are antibody-targeted: inebilizumab (anti-CD19) is in Phase 3 testing for NMDAR-encephalitis (ExTINGUISH trial); bortezomib (proteasome inhibitor) is used for refractory plasma-cell-driven disease; daratumumab (anti-CD38) is being explored. The therapeutic frontier in autoimmune encephalitis is depleting the cells that produce the offending antibodies more efficiently than rituximab does — not adding compounds with no antibody-axis activity.